FDA Brief

Warning letters Drugs

FDA warning letter to

Guangzhou Shiruoni Cosmetics Co., Ltd

High riskIssued Dec 7, 2021Posted Dec 21, 2021Center for Drug Evaluation and Research | CDER

Guangzhou Shiruoni Cosmetics' hand sanitizer labeled as 75% isopropyl alcohol contained ethanol instead and was misbranded as FDA-approved.

What happened

FDA tested a batch of IMPACTA HEALTH HAND SANITIZER after it was detained and refused admission at the U.S. border; the label claimed 75% isopropyl alcohol but testing found about 67% ethanol and no isopropyl alcohol. FDA also found the firm's webpage described the product as "FDA-Approved Hand Sanitizer," which it is not. In a December 17, 2020 teleconference, the firm said its labeling employees cannot read English and that it does not follow 21 CFR Parts 210 and 211 to make its hand sanitizers.

What FDA found

  1. The product was labeled as containing 75% isopropyl alcohol, but testing found no isopropyl alcohol and about 67% ethanol, so the active ingredient was swapped.

    FD&C Act section 501(d)(2), 21 U.S.C. 351(d)(2)
  2. Because the ingredient was substituted, the firm's quality assurance is not working as required by current good manufacturing practice (CGMP, the FDA rules for how drugs are made).

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  3. The firm told FDA it does not follow the CGMP regulations in 21 CFR Parts 210 and 211 when making its hand sanitizers.

    21 CFR Parts 210 and 211
  4. The label and website falsely suggest the product is FDA-approved.

    FD&C Act section 502(a), 21 U.S.C. 352(a)
  5. The label does not list ethanol, which testing found in the product.

    FD&C Act section 502(e)(1)(A), 21 U.S.C. 352(e)(1)(A)
  6. The stated amount of isopropyl alcohol on the label does not match what the product actually contains.

    FD&C Act section 502(a), 21 U.S.C. 352(a)

What FDA wants

FDA asks the firm to respond in writing within 15 working days with an investigation into how the isopropyl alcohol was replaced with ethanol, a list and full reconciliation of all hand sanitizer batches shipped to the United States, and complete batch records. FDA also strongly recommends hiring a qualified CGMP consultant to audit the operation if the firm intends to make drugs for the U.S. market again.

Who should pay attention

  • distributors and importers that buy hand sanitizer from foreign contract manufacturers
  • retailers and brands selling consumer antiseptic hand rubs
  • U.S. agents and importers listed on FDA registrations for foreign drug makers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Gadal Laboratories Inc.

    FDA warned Gadal Laboratories of CGMP violations at its Miami drug plant, including unqualified suppliers and contamination risks in pediatric OTC drugs.

    High risk
  2. Daxal Cosmetics Private Limited

    FDA warns Daxal Cosmetics for refusing records on over-the-counter drugs, including toothpaste, at risk for diethylene glycol and ethylene glycol contamination.

    High risk
  3. American Cleaning Solutions

    FDA warned American Cleaning Solutions after a 2022 inspection found hand sanitizer made with inadequate cleaning, unvalidated processes, and substituted ethanol.

    High risk
  4. Jose Miguel Gutierrez Salas

    FDA says hand sanitizer declared made by Jose Miguel Gutierrez Salas had methanol, not ethanol, and firm was not FDA-registered.

    High risk